Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TWST.

← Back to Free Index

TWST

Analysis as of: 2025-12-27

Twist Bioscience Corporation

Twist Bioscience manufactures synthetic DNA products and sells NGS sample-prep/target-enrichment tools plus antibody discovery offerings.

automation biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

From DNA supplier to workflow trust layer

Execution is improving (growth plus margin), and the next step is monetizing trust: reliability, auditability, and workflow integration. If profitability lands on schedule, a tools-peer re-rate is plausible by 2030.

Analysis

Thesis

As AI makes “designing biology” cheap, Twist can be the scaled, trusted “biology fulfillment + verification” layer—compounding SynBio/NGS share while moving up-stack into higher-trust nucleic-acid supply and compliance-grade workflows that unlock a durable re-rate if FY26 EBITDA breakeven is hit.

Last Economy Alignment

AI increases the number of designs that must be built; Twist monetizes the scarce piece: reliable, auditable physical synthesis + workflow trust (biosecurity/QA).

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied Multiple (to 2030)

3.1x (from 5 most recent analyses)

Reasoning

Twist is already scaling core demand (SynBio write + NGS tools) and is now positioned to productize “trust” (performance guarantees, auditability, security-minded supply) which matters more as AI accelerates experiment velocity. The upside case is less about inventing a new market and more about converting demonstrated gross-margin gains into self-funding growth, then earning a higher-quality Life Science Tools valuation as profitability becomes repeatable.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The growth plan relies on converting operational gains into durable profitability while defending price in commoditizing categories. The highest-impact risks are (1) competitive pricing/mix deterioration in NGS and synthesis, (2) timing slippage on regulated/enterprise adoption, and (3) manufacturing continuity risk from single-source components and multi-site scale complexity.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Announced a presentation at the J.P. Morgan 2026 Healthcare Conference (scheduled for Jan 12, 2026).
Launched research-grade plasmid DNA prep products targeting nucleic-acid therapeutics research workflows.
No new financial guidance disclosed in the last 7–10 days; focus remains on FY26 adjusted EBITDA breakeven trajectory.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

12-Month Price Target

$44.88

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case